Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.40 |
| ▸ | IDH1 | O75874 | 3/20 | 0.35 |
| ▸ | ACACB | O00763 | 6/20 | 0.35 |
| ▸ | NTSR1 | P30989 | 3/20 | 0.34 |
| ▸ | BPTF | Q12830 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1887404 | 0.86 | USP30 (0.41) | USP30IDH1ACACBNTSR1ADORA2A | |
| SCHEMBL20004371 | 0.74 | BPTF (0.57) | USP30ACACBNTSR1BPTFADORA2A | |
| SCHEMBL3121487 | 0.74 | USP30 (0.47) | USP30ACACBNTSR1ADORA2A | |
| SCHEMBL18929109 | 0.73 | ADRA2C (0.50) | USP30ACACBNTSR1BPTFADORA2A | |
| SCHEMBL25015826 | 0.73 | NOTUM (0.57) | USP30ACACBNTSR1 | |
| SCHEMBL7947367 | 0.72 | USP30 (0.47) | USP30ACACBNTSR1BPTFADORA2A | |
| SCHEMBL16426133 | 0.72 | SNCA (0.38) | — | |
| SCHEMBL368100 | 0.71 | LPL (0.33) | USP30ACACBMCHR1 | |
| SCHEMBL13486520 | 0.70 | NOTUM (0.50) | USP30ACACBNTSR1 | |
| SCHEMBL24681269 | 0.70 | USP30 (0.40) | USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008298-B2 | Pyrrolopyrazine kinase inhibitors | Roche Palo Alto (US) | 2011-08-30 | — | — | US | disclosed |
| US-8008298-B2 | Pyrrolopyrazine kinase inhibitors | Roche Palo Alto (US) | 2011-08-30 | — | — | US | disclosed |
| US-20100267666-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2010-10-21 | — | — | US | disclosed |
| US-20100267666-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267666-A1 | Pyrrolopyrazine kinase inhibitors | SYK, ZAP70, TYK2 | USP30 957/4885IDH1 2093/4885ACACB 4042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.